Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.

Novavax Inc. jumped in early trading after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was delayed and US Health and Human Services Secretary Robert F.

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or friend.